4D Molecular Therapeutics, Inc.

FDMT

$10.95

Name : 4D Molecular Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $625,629,056.00

EPSttm : -3.75

4D Molecular Therapeutics, Inc.

$10.95

1.48%

$0.16

Float Short %

8.43

Margin Of Safety %

Put/Call OI Ratio

0.43

EPS Next Q Diff

-1.62

EPS Last/This Y

-0.28

EPS This/Next Y

-0.22

Price

10.96

Target Price

31.62

Analyst Recom

1.5

Performance Q

66.67

Relative Volume

0.77

Beta

2.95

Ticker: FDMT

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	FDMT	11.27	0.10	0.11	3318
2025-10-21	FDMT	11.23	0.11	0.08	3378
2025-10-22	FDMT	10.5	0.10	2.40	3537
2025-10-23	FDMT	9.99	0.10	0.18	3531
2025-10-24	FDMT	11.35	0.10	0.14	3592
2025-10-27	FDMT	12.27	0.11	0.10	3802
2025-10-28	FDMT	11.95	0.11	0.44	3931
2025-10-29	FDMT	11.38	0.11	2.40	3974
2025-10-30	FDMT	11.34	0.11	0.00	3980
2025-10-31	FDMT	11.5	0.11	0.01	3981
2025-11-03	FDMT	11.23	0.11	1.79	4166
2025-11-04	FDMT	10.73	0.18	7.19	4630
2025-11-05	FDMT	10.51	0.30	0.00	5112
2025-11-06	FDMT	10.9	0.30	1.84	5118
2025-11-07	FDMT	10.5	0.37	0.01	5396
2025-11-10	FDMT	10.16	0.38	6.05	5265
2025-11-11	FDMT	10.8	0.44	0.14	5498
2025-11-12	FDMT	10.98	0.43	0.04	5506
2025-11-13	FDMT	10.27	0.43	0.00	5511
2025-11-14	FDMT	10.78	0.43	0.01	5559
2025-11-17	FDMT	10.95	0.43	0.29	5534
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	FDMT	11.27	-24.6	-	-3.68
2025-10-21	FDMT	11.24	-24.6	-	-3.68
2025-10-22	FDMT	10.52	-24.6	-	-3.68
2025-10-23	FDMT	10.00	-24.6	-	-3.68
2025-10-24	FDMT	11.36	-24.6	-	-3.68
2025-10-27	FDMT	12.27	-24.6	-	-3.68
2025-10-28	FDMT	11.97	-24.6	-	-3.68
2025-10-29	FDMT	11.39	-24.6	-	-3.68
2025-10-30	FDMT	11.32	-24.6	-	-3.68
2025-10-31	FDMT	11.50	-24.6	-	-3.68
2025-11-03	FDMT	11.23	-24.6	-	-3.68
2025-11-04	FDMT	10.73	-24.6	-	-3.68
2025-11-05	FDMT	10.49	-24.6	-	-3.68
2025-11-06	FDMT	10.90	-24.6	-	-3.68
2025-11-07	FDMT	10.50	-24.6	-	-3.67
2025-11-10	FDMT	10.17	-24.6	-	-3.67
2025-11-11	FDMT	10.80	-24.6	-	-3.67
2025-11-12	FDMT	10.97	-24.6	-	-3.67
2025-11-13	FDMT	10.27	-24.6	-	-3.67
2025-11-14	FDMT	10.78	30.8	-	-3.43
2025-11-17	FDMT	10.96	40.9	-	-3.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	FDMT	-0.12	-6.87	10.54
2025-10-21	FDMT	-0.16	-6.87	10.54
2025-10-22	FDMT	-0.16	-6.87	10.54
2025-10-23	FDMT	-0.16	-6.87	10.54
2025-10-24	FDMT	-0.16	-6.87	10.54
2025-10-27	FDMT	-0.12	-8.37	10.19
2025-10-28	FDMT	-0.17	-8.37	10.19
2025-10-29	FDMT	-0.17	-8.37	10.19
2025-10-30	FDMT	-0.17	-8.37	10.19
2025-10-31	FDMT	-0.17	-8.37	10.19
2025-11-03	FDMT	-0.17	-7.88	10.19
2025-11-04	FDMT	-0.17	-7.88	10.19
2025-11-05	FDMT	-0.17	-7.88	10.19
2025-11-06	FDMT	-0.17	-7.88	10.19
2025-11-07	FDMT	-0.17	-7.88	10.19
2025-11-10	FDMT	-0.17	-8.89	10.19
2025-11-11	FDMT	-0.17	-8.89	10.19
2025-11-12	FDMT	-0.17	-8.89	10.32
2025-11-13	FDMT	-0.14	-8.89	0
2025-11-14	FDMT	-0.14	-8.89	8.44
2025-11-17	FDMT	-0.14	-4.35	8.43
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.69

Avg. EPS Est. Current Quarter

-0.53

Avg. EPS Est. Next Quarter

-0.93

Insider Transactions

-0.14

Institutional Transactions

-4.35

Beta

2.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.1

Max Drawdown 5-Year %

Target Price

31.62

P/E

Forward P/E

PEG

P/S

5213.6

P/B

1.39

P/Free Cash Flow

EPS

-3.94

Average EPS Est. Cur. Y

-3.26

EPS Next Y. (Est.)

-3.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-174314.17

Relative Volume

0.77

Return on Equity vs Sector %

-83.6

Return on Equity vs Industry %

-68.7

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

0.43

EBIT Estimation

4D Molecular Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 227

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today

news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance

stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market

stock prices FDMT premarket after hours

ticker FDMT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FDMT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y